# The Efficacy and Safety of Atorva® 20mg Versus Lipitor® 20mg

Study · id `cardio:ct-nct01624207` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01624207](<https://clinicaltrials.gov/study/NCT01624207>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01624207

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 376 participants.

## Technical summary

Registry record NCT01624207. Randomized; no masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2011-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 376 participants (enrolled count; ClinicalTrials.gov record NCT01624207, source copy `cardio:ctgov-nct01624207-2013-12-17`, retrieved 2026-10-31)
- Start date: 2010-03 (registry gives no type) (ClinicalTrials.gov record NCT01624207, source copy `cardio:ctgov-nct01624207-2013-12-17`, retrieved 2026-10-31)
- Primary completion: 2011-01 (actual) (ClinicalTrials.gov record NCT01624207, source copy `cardio:ctgov-nct01624207-2013-12-17`, retrieved 2026-10-31)
- Completion: 2011-04 (actual) (ClinicalTrials.gov record NCT01624207, source copy `cardio:ctgov-nct01624207-2013-12-17`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT01624207, source copy `cardio:ctgov-nct01624207-2013-12-17`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01624207-2013-12-17`, retrieved 2026-10-31)

## The registry's words

- Brief title: The Efficacy and Safety of Atorva® 20mg Versus Lipitor® 20mg
- Condition: Hypercholesterolemia
- Intervention (Drug): generic formulation of atorvastatin (Atorva®)
- Intervention (Drug): branded formulation of atorvastatin (Lipitor®)
- Lead sponsor: Seoul National University Hospital
- Lead sponsor class: OTHER
- Collaborator: Yuhan corp., Seoul, Korea
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Seoul National University Hospital (`cardio:org-seoul-national-university-hospital`)

## Provenance

Content hash: 988083cd14e70001f34345f66a1c570e45ce56f179749df45203065d64a00bd2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
